30 September 2025 in Meditsinskiy sovet = Medical Council
Introduction. Psoriasis and psoriatic arthritis are chronic immune-inflammatory diseases accompanied by a high frequency of cardiovascular comorbidity. Early diagnosis of subclinical atherosclerosis in young patients is of particular importance, when traditional risk stratification scales often underestimate its severity.Aim. To assess the cardiovascular risk and prevalence of subclinical atherosclerosis in patients with various forms of psoriasis and psoriatic arthritis.Materials and methods. The study included 106 patients divided into three groups: with pustular palmoplantar psoriasis (n = 31), with plaque psoriasis and psoriatic arthritis (n = 37), with plaque psoriasis without arthritis (n = 38). All patients underwent ultrasound duplex scanning of the brachiocephalic and peripheral arteries, lipid spectrum analysis and risk stratification according to the Framingham-30 scale. Statistical analysis included correlation and regression methods.Results. Subclinical atherosclerosis was detected in 45.9% of patients with psoriatic arthritis, in 41.9% with pustular psoriasis and only in 23.7% with plaque psoriasis. At the same time, lesions of the arteries of the lower extremities prevailed over changes in the carotid arteries. Patients with pustular psoriasis had higher levels of total cholesterol and LDL, but the atherogenicity coefficient values did not differ between the groups. The Framingham-30 scale demonstrated high sensitivity but low specificity in predicting vascular changes.Conclusions. In young patients with psoriatic arthritis and pustular psoriasis, the frequency of subclinical atherosclerosis is significantly higher than in isolated plaque psoriasis. The obtained data confirms the necessity to use instrumental methods for assessing vascular status along with traditional risk scales, which will allow for timely identification and correction of cardiovascular risk factors.
12 June 2026 in Vestnik dermatologii i venerologii
Background: Palmoplantar pustular psoriasis (PPPP) is considered a clinically and pathogenetically distinct form of psoriasis; however, its molecular patterns remain insufficiently understood. The role of circulating small non-coding RNA molecules (microRNAs) in the development of phenotypic differences between plaque psoriasis and PPPP has not been fully elucidated. Aim: To evaluate plasma microRNA expression patterns in patients with plaque psoriasis and PPPP and to identify differences between the clinical disease subtypes. Methods: A comparative study including 38 patients with plaque psoriasis and 31 patients with PPPP was conducted. Plasma expression levels of hsa-miR-126-5p, hsa-miR-210-3p, hsa-miR-10b-5p, and hsa-miR-130a-3p were measured using quantitative real-time polymerase chain reaction with relative expression estimated using the 2−ΔΔCt method. Statistical processing was performed using parametric and non-parametric tests adjusted for multiple comparisons. Results: Patients with PPPP have demonstrated a statistically significant increased expression of hsa-miR-126-5p (p = 0.04) and hsa-miR-210-3p (p = 0.01) compared with plaque psoriasis. The differences in hsa-miR-10b-5p and hsa-miR-130a-3p expression were not statistically significant. Stratification by the PASI score has shown that the expression profile in PPPP was comparable to that observed in more severe forms of plaque psoriasis. Conclusion: The identified changes in microRNA expression indicate molecular differences between the clinical phenotypes of psoriasis. Thus, hsa-miR-126-5p and hsa-miR-210-3p may be considered as potential markers of molecular activity in PPPP and require further investigation.
31 May 2026 in Consilium Medicum
Background. Psoriasis is a systemic immune-mediated inflammatory disease with a high risk of comorbid conditions, among which metabolic syndrome (MS) is of particular importance. The association of MS with plaque psoriasis has been best studied, while data on its prevalence in rare clinical variants, particularly palmoplantar pustular psoriasis (PPP), are limited. Aim. To study the prevalence of metabolic syndrome and its components in young patients with various forms of psoriasis. Materials and methods. The study included 106 patients with psoriasis, divided into three groups: Group 1: 31 patients with palmoplantar pustular psoriasis, Group 2: 37 patients with plaque psoriasis complicated with psoriatic arthritis, and Group 3: 38 patients with plaque psoriasis without arthritis. All patients underwent an assessment of clinical and demographic parameters, skin disease severity using the PASI index, blood lipid profile parameters, fasting glucose and insulin levels, and calculation of the HOMA-IR insulin resistance index. Metabolic syndrome was diagnosed using unified international criteria and the criteria of the All-Russian Scientific Society of Cardiologists (VNOC). Results. The prevalence of metabolic syndrome according to international criteria was 42.0% in the PPP group, 37.8% in patients with plaque psoriasis and psoriatic arthritis, and 26.3% in patients with plaque psoriasis without arthritis. According to the All-Russian Society of Cardiologists criteria, similar figures were 45.2, 40.5, and 31.6%, respectively. Patients with PPP and patients with psoriatic arthritis had statistically significantly higher levels of insulin and HOMA-IR index compared with patients with isolated plaque psoriasis. Insulin levels and HOMA-IR index were statistically significantly higher in groups 1 and 2 (8.0 [5.47; 13.6] and 11.55 [9.90; 16.08]; 1.99 [1.22; 3.93] and 2.89 [2.43; 4.53], respectively) compared with group 3 (3.56 [2.29; 6.63]; 0.83 [0.67; 1.66]). Conclusions. Hyperinsulinemia and insulin resistance in patients with PPP and MS likely reflect the existing pathogenetic differences between pustular and plaque psoriasis. The findings may be useful for clinical practice when screening for metabolic disorders in young patients.
24 June 2026 in Modern Rheumatology Journal
3 June 2026 in Medical alphabet
Background. Psoriasis (PsO), psoriatic arthritis (PsA), and metabolic syndrome (MetS) share common immune-inflammatory mechanisms. MicroRNAs are considered potential molecular links integrating inflammatory and metabolic disturbances. Objective. To evaluate the expression of hsa-miR‑210–3p, hsa-miR‑10b‑5p, hsa-miR‑130a‑3p, and hsa-miR‑126–5p in young patients with PsO and PsA, taking into account the presence of MetS. Materials and methods . The study included 38 patients with PsO and 37 with PsA under 45 years of age. Plasma microRNA expression was assessed using RT-qPCR (2^-ΔΔCt method). PERMANOVA, SIMPER, ROC analysis, and correlation analysis were performed. Results . The results of paired multivariate PERMANOVA analysis for the PsO and PsA groups demonstrated statistically significant differences in the overall expression pattern of the studied microRNAs (p=0.003). Statistically significant differences in expression between patients with PsO and PsA were found for two microRNAs: miR‑130a‑3p and miR‑10b‑5p: 57.3 % (p=<0.001) and 22.5 % (p=0.021). The presence of MS in patients with PsA was accompanied by an increase in the expression of miR‑10b‑5p (FC=0.68, p=0.03; log2(2^(–dct) PsA without MS –0.56 [–1.387; –0.198] compared to PsA with MS –1.465 [–1.842; –0.67], p=0.032). The expression level of miR‑130a‑3p positively correlated with glucose, insulin and HOMA-IR. Conclusion. hsa-miR‑130a‑3p and hsa-miR‑10b‑5p may reflect the transition from cutaneous to articular forms of psoriatic disease and participate in the integration of metabolic and inflammatory pathways, representing potential biomarkers of PsO-to-PsA transformation.